Buflomedil in Arterial Occlusive Disease: Results of a Controlled Multicenter Study-Reference-Cited by-同舟云学术

Buflomedil in Arterial Occlusive Disease: Results of a Controlled Multicenter Study

Published:1984-08 Issue:8 Volume:35 Page:500-505
ISSN:0003-3197
Container-title:Angiology
language:en
Short-container-title:Angiology

Author:

Trübestein G.¹,Balzer K.²,Bisler H.³,Klüken N.⁴,Muller-Wiefel H.⁵,Unkel B.⁶,Mahfoud Y.⁶,Ziegler W.⁷

Affiliation:

1. Medizinische Universitäts-Poliklinik, Bonn, Federal Republic of Germany

2. Evangelisches Krankenhaus Mülheim, Rühr, Federal Republic of Germany

3. Knappschaftskrankenhaus Bottrop, Bottrop, Federal Republic of Germany

4. Abteilung fur Dermatologie und Angiologie der Universitäts-Kliniken Essen, Essen, Federal Republic of Germany

5. Johannes-Hospital Duisburg, Duisburg, Federal Republic of Germany

6. Marienhospital y Gelsenkirchen, Gelsenkirchen, Federal Republic of Germany

7. Institut für Forschungsplanung - CH Bettingen-Basel, Switzerland

Abstract

In a double-blind, randomised multicentre study buflomedil, a vasoactive substance, was compared with placebo in the treatment of 93 patients with chronic arterial occlusive disease. After a run-in period of four weeks the patients received either buflomedil (600 mg daily) or placebo over 12 weeks. The pain-free and the total walking distances improved significantly in both groups. However, the differences in the improvement between the two groups were highly signifi cant and in favour of buflomedil: for the pain-free walking distance p<0.001 and for the total walking distance p<0.01. The results indicate that buflomedil has a beneficial effect on the symptoms and lengthens the walking distance in patients with arterial occlusive disease.

Publisher

SAGE Publications

Subject

Cardiology and Cardiovascular Medicine

Link

http://journals.sagepub.com/doi/pdf/10.1177/000331978403500805

Reference20 articles.

1. Sunder-Plassmann L., Endrich B., Hesler Fv, Messmer K.: Resistance of collateral vessels in experimental occlusive disease: Dilation versus dilution. In: Microcirculation and Ischemic Vascular Disease. Clinical and Therapeutic Approaches, ed. by Couto B, Buzzi A, Degni M. New York, Biomedical Information Corporation, 1982, pp. 427-44.

2. Wurzinger LJ: Wirkungen von Buflomedil auf die spontane und auf die adrenalininduzierte Plättchenaggregation in vitro und nach intravenöser Verabreichung unter Heparin-Antikoagulation . In: Mikrozirkulation und Arterielle Verschlußkrankheiten , ed. by Messmer K, Fagrell B. Basel, Karger, 1981, pp. 77-82.

3. Effects of Buflomedil on Erythrocyte Deformability

4. Endrich B., Schosser R., Beyer J., et al: Einfluss von Buflomedil auf den Gesamt-O2-Verbrauch, die regionale Durchblutung und den Gewebs-pO2. In: Mikrozirkulation und Arterielle Verschlußkrankheiten, ed. by Messmer K, Fagrell B. Basel, Karger, 1981, pp. 154-9.

5. Mantel N., Haenszel W.: Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute 719-48, 1959.

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Buflomedil for intermittent claudication;Cochrane Database of Systematic Reviews;2013-03-28

2. Silence of the Limbs: Pharmacological Symptomatic Treatment of Intermittent Claudication;Current Vascular Pharmacology;2010-05-01

3. Current Management of Intermittent Claudication: The Role of Pharmacological and Nonpharmacological Symptom-Directed Therapies;Current Vascular Pharmacology;2009-07-01

4. Pharmacologic Therapy for Intermittent Claudication;Pharmacotherapy;2009-05

5. Bias in Benefit-Risk Appraisal in Older Products;Drug Safety;2009